Christin Whalen, RN, BSN, OCN
Dana-Farber Cancer InstituteAuthored Items
Nicole Houston, BSN, RN, CCRP, Irene Ekwede, MSN, BSN, RN, Stephanie Morrissey, RN, BSN, Brittany Bowes, RN, BSN, Eleni Rokakis, RN, BSN, Ruth Phillips, RN, BSN, MS, OCN, Ellie Strock, ANP-BC, FAANP, CDE, Christin Whalen, RN, BSN, OCN
November 2018 Vol 9, NO 11
Cediranib-olaparib in combination has been shown to cause rapidly escalating hypertension and severe diarrhea in patients treated for ovarian cancer.
Last modified: December 17, 2018